Russian Lip Filler Technique: What It Is and Who Offers It

The honest definition is a negative one.

A MedSpaStandard search of PubMed in October 2026 found no peer-reviewed study of a "Russian lip technique" by that name, and no FDA label or filler product label we checked mentions it.

What injector marketing usually describes as the Russian technique is vertical injection, in contrast to other placements.

Because we found nothing in a label or a study that pins the name to a defined method, there is no standard definition a clinic's version has to match.

"Russian lip filler" is also not a filler product.

The fillers used in lip augmentation are FDA-approved products, each with its own labeled indications — and no label we checked mentions the Russian technique by name.

The same applies to other style names: we could not confirm a medical definition for "butterfly lip filler" either.

The useful question at any consultation is which FDA-approved filler a provider would use and where they would place it — not what the style is called.

Since our search found no peer-reviewed study of the technique by name, a Russian-versus-classic comparison table would be marketing, not evidence.

What can be compared is what studies have actually measured about injection placement.

The most relevant study never uses the word "Russian." A 2026 ultrasound study of 126 people in London and Amsterdam measured the lip's subcutaneous layer — the layer just under the skin — at an average of under 1 mm, which is one reason hyaluronic-acid lip filler often ends up inside the lip muscle instead.

In that study, vertical injection techniques were associated with deeper filler deposition, hypervascularity and evidence of migration.

Vertical injection is how the Russian technique is usually described, but the study tested placement, not the brand name — it cannot tell you whether one named style outperforms another.

Whatever the style, the checkable facts are in the product label. Restylane was the first US filler with a lip indication, approved in 2011.

Restylane Kysse followed on March 26, 2020, for lip augmentation and correction of upper perioral lines in patients over 21.

RHA 3, approved in 2023, is the only RHA product with a lip indication — the vermilion body, vermilion border and oral commissures, in adults 22 or older.

For lip filler as a whole — the approved products, pricing structure and duration figures — see our lip filler guide.

And because deeper placement showed up alongside migration signs in the ultrasound study, our page on lip filler migration covers what migration looks like and what causes it.

We cannot tell you whether this style suits your face — our search found no study that defines who it is for, and that call belongs to a licensed provider who has examined you.

What the sources do define is who fillers in general have been studied and approved for.

FDA says dermal fillers are approved for adults aged 22 or older, with each product label setting the exact minimum age.

Among the lip fillers named above, Restylane and Restylane Kysse are approved for patients over 21, while RHA 3's lip approval is for adults 22 or older.

FDA also states that filler safety is unknown during pregnancy and breastfeeding, in people under 22, and in people prone to keloid or hypertrophic scarring, and that treatment should be delayed if the skin where you'd be treated is inflamed or infected.

The disclosure items are FDA's own list: the agency says people should tell the provider about bleeding disorders, severe allergies or anaphylaxis, and allergies to lidocaine, collagen, eggs, animal products or bacteria before treatment.

The pregnancy, scarring and skin-infection items above are ones FDA flags as safety unknowns or reasons to delay rather than disclosure items.

If several apply to you, that does not settle anything by itself — it tells you which questions to put to the provider first.

Because our search found no study testing this technique by name, its risk profile is not separately documented.

What is documented is lip filler risk in general.

In the Restylane Kysse US pivotal trial, the most common diary-reported lip reactions after initial treatment were swelling in 90.2% of subjects, tenderness in 87.4% and bruising in 85.8% — the majority tolerable and lasting less than 2 weeks.

On volume: we found no label, professional-body or peer-reviewed source that gives a standard filler amount per lip, per area or per style, so any "Russian lips take X syringes" figure you see is an estimate from someone, not a tested number.

The volumes that do exist are trial medians and label maximums tied to one product.

In the Restylane Kysse trial (273 subjects randomized against a control), the median volume for initial treatment plus touch-up was 0.90 mL in the upper lip and 0.80 mL in the lower lip, and the Kysse label sets a recommended maximum of 3 mL for the lips and 6 mL per patient per treatment including the perioral area.

How often do serious problems occur?

In a 2021 JAMA Dermatology study, 370 US board-certified dermatologists reporting 1.7 million filler syringes observed 1 occlusion per 6,410 one-mL syringe injections with needles and 1 per 40,882 with cannulas; the rate never exceeded 1 per 5,000 syringes for any filler type, lips were among the sites most often affected, and 85% of occlusions had no long-term sequelae.

Those are self-reported figures from experienced dermatologists, not a universal rate for every injector.

FDA advises choosing a licensed health care provider with dermatology or plastic-surgery experience who is trained in filler injection, and says filler injection should be considered a medical procedure, not a cosmetic treatment.

Who may inject — and under whose supervision — is set by state law, and the rules differ from state to state.

AmSpa describes a common delegation model in which NPs inject with documented training under a collaborative agreement or full practice authority, and RNs — in some states LPNs/LVNs or medical assistants too — inject only with documented training, after a patient exam and a treatment order from a physician (or a delegated PA/NP), with the physician on site or promptly reachable.

That description is a general one and is not true in every state — several states bar LPNs/LVNs or medical assistants from injecting.

Because we found no label or study that defines the technique, the injector's method is worth probing directly.

These are the questions that get at it:

On that third question, FDA tells injectors to know the signs of intravascular injection, keep an updated plan for treating it (on-site treatment and/or immediate referral), and stop injecting if warning signs such as skin blanching, vision change, stroke signs or unusual pain appear.

A provider who can answer it specifically is showing you more than any style name does.

Two FDA warnings belong at the end of any filler search: needle-free devices such as "hyaluron pens" are not approved for injecting dermal fillers, and no filler is approved for over-the-counter sale — FDA says people should not inject themselves or buy filler online.